Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions in the US
Publication: Journal of Comparative Effectiveness Research
Abstract
Glucagon-like peptide 1 receptor agonists and glucagon-like peptide 1/gastric inhibitory polypeptide receptor agonists offer weight reduction and associated health benefits that, if sustained over time, have the potential to markedly improve population health. However, over 40% of US adults have obesity, translating into more than 100 million potential new users of obesity medications. Standing in the way of the major opportunity to improve health for these individuals is the massive and likely ongoing cost of treating such a large segment of the population, even though use of the treatments is estimated to be cost–effective over a lifetime. This paper analyzes the range of emerging market approaches and policy reforms that have the potential to help the broader US health system achieve affordable and equitable access to these medications, and the relative advantages, barriers and possible unintended consequences of each approach. We seek to present policymakers and industry leaders with insights and lessons learned from experts while offering a menu of options for the future that will help all stakeholders play an active part in an innovative future of pricing, coverage and payment for new obesity medications.
Supplementary Material
File (supplementary material.docx)
- Download
- 22.61 KB
References
1.
Institute for Clinical and Economic Review. Medications for obesity management: effectiveness and value. (2022). Available at: https://icer.org/wp-content/uploads/2022/03/ICER_Obesity_Final_Evidence_Report_and_Meeting_Summary_122223.pdf
2.
UBS Investment Bank. Glp-1: a medication worth $126 billion in sales by 2029? (2024). Available at: https://www.ubs.com/global/en/investment-bank/insights-and-data/2024/glp-1-a-medication.html
3.
PwC. From molecules to milestones: reinventing for the future of weight loss drugs. (2024). Available at: https://www.pwc.com/us/en/services/consulting/business-model-reinvention/glp-1-trends-and-impact-on-business-models.html
4.
National Insitutes of Health. Our biggest health challenges. (2023). Available at: https://www.nih.gov/about-nih/what-we-do/nih-turning-discovery-into-health/our-biggest-health-challenges
5.
Alexander GC, Karlawish J. The problem of aducanumab for the treatment of Alzheimer disease. Ann. Intern. Med. 174(9), 1303–1304 (2021).
6.
Fryar CD, Carroll MD, Afful J. Prevalence of overweight, obesity, and severe obesity among adults aged 20 and over: United States, 1960–1962 through 2017–2018. In: National Center for Health Statistics: Health E-Stats, Center for Disease Control (2020). Available at: https://www.cdc.gov/nchs/data/hestat/obesity-adult-17-18/overweight-obesity-adults-H.pdf
7.
Center for Disease Control. Obesity and overweight. (2024). Available at: https://www.cdc.gov/nchs/fastats/obesity-overweight.htm
8.
Ward ZJ, Bleich SN, Long MW, Gortmaker SL. Association of body mass index with health care expenditures in the united states by age and sex. PLoS One 16(3), e0247307 (2021).
9.
Cawley J, Biener A, Meyerhoefer C et al. Direct medical costs of obesity in the United States and the most populous states. J. Manag. Care Spec. Pharm. 27(3), 354–366 (2021).
10.
Bhattacharya J, Sood N. Who pays for obesity? J. Econ. Perspect. 25(1), 139–157 (2011).
11.
Kuehn B. Obesity rates increasing. JAMA 320(16), 1632 (2018).
12.
Phelan S, Burgess D, Yeazel M et al. Impact of weight bias and stigma on quality of care and outcomes for patients with obesity. Obes. Rev. 16(4), 319–326 (2015).
13.
Puhl RM, Heuer CA. The stigma of obesity: a review and update. Obesity 17(5), 941–964 (2009).
14.
Latif W, Lambrinos KJ, Patel P, Rodriguez R. Compare and contrast the glucagon-like peptide-1 receptor agonists (GLP1ras). Stat Pearls Publishing (2025). 25 February 2024. Available at: https://www.ncbi.nlm.nih.gov/books/NBK572151/
15.
Food and Drug Administration. FDA approves new medication for chronic weight management. (2023). Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
16.
Gleason PP, Urick BY, Marshall LZ et al. Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes. JMCP 30(8), 860–867 (2024).
17.
Marshall LZ, Urick BY, Friedlander N et al. Two-year persistent glucagon-like peptide-1 agonist obesity without diabetes treatment: clinical outcomes among commercially insured. In: AMCP Annual Meeting, Prime Therapeutics, TX, USA (2025). Available at: https://www.primetherapeutics.com/documents/d/primetherapeutics/4085-d_amcp_spring25_glp1apersistentclinicaloutcomes_r4-1
18.
Shor R, Mihalache A, Noor A et al. Glucagon-like peptide-1 receptor agonists and risk of neovascular age-related macular degeneration. JAMA Oph. doi: (2025). (Online ahead of print).
19.
Kelly CA, Sipos JA. Approach to the patient with thyroid nodules: considering GLP-1 receptor agonists. J. Clin. Endocrinol. Metab. 110(6), e2080–e2087 (2025).
20.
Novo Nordisk. Novo Nordisk introduces Novocare® Pharmacy, lowering cost of all doses of FDA-approved Wegovy® (semaglutide) to $499 per month and offering easy home delivery for cash-paying patients. (2025). Available at: https://www.novonordisk-us.com/media/news-archive/news-details.html?id=915288
21.
Eli Lilly. Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients. (2025). Available at: https://investor.lilly.com/news-releases/news-release-details/lilly-launches-additional-zepbound-vial-doses-and-offers-new
22.
Dellgren JL, Persad G, Emanuel EJ. International coverage of GLP-1 receptor agonists: a review and ethical analysis of discordant approaches. Lancet 404(10455), 902–906 (2024).
23.
US Senate Committee on Health, Education, Labor & Pensions. Media advisory: sanders to lead help committee hearing on outrageous Ozempic and Wegovy prices with Novo Nordisk CEO. (2024). Available at: https://www.help.senate.gov/dem/newsroom/press/media-advisory-sanders-to-lead-help-committee-hearing-on-outrageous-ozempic-and-wegovy-prices-with-novo-nordisk-ceo
24.
Alhiary R, Kesselheim AS, Gabriele S et al. Patents and regulatory exclusivities on GLP-1 receptor agonists. JAMA 330(7), 650–657 (2023).
25.
Allen A. Why millions are trying alternatives to Big Pharma's weight loss drugs – CBS News. (2024). Available at: https://www.cbsnews.com/news/fda-approved-alternatives-ozempic-wegovy-mounjaro-compounding-pharmacies/
26.
Knibbs K. It's shockingly easy to buy off-brand Ozempic online, even if you don't need it. Wired. (2024). Available at: https://www.wired.com/story/glp1-ozempic-wegovy-semaglutide-compounding-pharmacies-hims-reflexmd-alan-meds-henry-ro-getthinmd/
27.
Allen A. Why millions are trying FDA-authorized alternatives to Big Pharma's weight loss drugs. KFF Health News (2024). Available at: https://kffhealthnews.org/news/article/glp1-compounding-pharmacies-wegovy-zepbound-copycat-drugs-shortages/
28.
Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss. (2024). Available at: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
29.
Obesity Medicine Association. Leading obesity expert organizations release statement to patients on compounded GLP-1 alternatives. (2024). Available at: https://obesitymedicine.org/blog/leading-obesity-expert-organizations-release-statement-to-patients-on-glp-1-compounded-alternatives/
30.
Neumiller JJ, Bajaj M, Bannuru RR et al. Compounded GLP-1 and dual gip/GLP-1 receptor agonists: a statement from the American Diabetes Association. Diabetes Care 48(2), 177–181 (2025).
31.
Food and Drug Administration. Declaratory order: resolution of shortages of semaglutide injection products (Ozempic and Wegovy). (2025). Available at: https://www.fda.gov/media/185526/download
32.
Sharma A. Eli Lilly resolves shortage for tirzepatide, potentially ending compounders' run. Endpoints News (2024). Available at: https://endpts.com/eli-lilly-resolves-shortage-for-tirzepatide-ending-compounders-run/
33.
Sutter S. US FDA employs familiar strategy in ending Novo's Wegovy, Ozempic shortage. Citeline (2025). Available at: https://insights.citeline.com/pink-sheet/compliance/distribution-supply-chain/us-fda-employs-familiar-strategy-in-ending-novos-wegovy-ozempic-shortage-XWRMJ2WTPNCXTEHHJEXJAJE2QY/
34.
Cubanski J, Williams E. Proposed coverage of anti-obesity drugs in Medicare and Medicaid would expand access to millions of people with obesity. KFF (2024). Available at: https://www.kff.org/policy-watch/proposed-coverage-of-anti-obesity-drugs-in-medicare-and-medicaid-would-expand-access-to-millions-of-people-with-obesity/
35.
Centers for Medicare & Medicaid Service. Medicare and Medicaid programs; contract year 2026 policy and technical changes to the Medicare advantage program, Medicare prescription drug benefit program, Medicare cost plan program, and programs of all-inclusive care for the elderly. (2025). Available at: https://public-inspection.federalregister.gov/2025-06008.pdf
36.
Sanger-Katz M, Robbins R. Trump rejects Biden plan to expand Medicare coverage for obesity drugs. New York Times (2025). Available at: https://www.nytimes.com/2025/04/04/health/trump-wegovy-obesity-drugs-medicare.html
37.
Liu BY, Rome BN. State coverage and reimbursement of antiobesity medications in Medicaid. JAMA 331(14), 1230–1232 (2024).
38.
Hinton E, Williams E, Raphael J et al. 50 state Medicaid budget survey fiscal years 2023–2024. KFF (2023). Available at: https://www.kff.org/report-section/50-state-medicaid-budget-survey-fy-2023-2024-pharmacy/
39.
Bannow T. More state Medicaid programs consider covering GLP-1 drugs. STAT (2024). Available at: https://www.statnews.com/2024/10/23/medicaid-wegovy-saxenda-glp-1-weight-loss-drugs/
40.
Carbajal E. 1% of ACA health plans cover GLP-1s for weight loss. KFF (2024). Available at: https://www.beckerspayer.com/payer/1-of-aca-health-plans-cover-glp-1s-for-weight-loss-kff/
41.
PSG. 2024 trends in drug benefit design report. (2024). psgconsults.com. Available at: https://www.psgconsults.com/industry-report/2024-trends-in-drug-benefit-design-report/
42.
Wilson R. Employers are worried about GLP-1s – most cover them anyway. Becker's Payer Issues (2024). Available at: https://www.beckerspayer.com/payer/employers-are-worried-about-glp-1s-most-cover-them-anyway/
43.
Klein HE. Rising costs lead insurers to drop weight loss drug coverage, further increasing patient burden. Am. J. Manag. Care 30(Spec. No. 10), SP781–SP782 (2024). 6 August 2024. Available at: https://www.ajmc.com/view/rising-costs-lead-insurers-to-drop-weight-loss-drug-coverage-further-increasing-patient-burden
44.
Goforth A. North Carolina ends coverage of new weight loss drugs for 750,000 state employees. BenefitsPRO (2024). Available at: https://www.benefitspro.com/2024/05/17/north-carolina-ends-coverage-of-glp-1-weight-loss-drugs-for-750000-state-employees/?slreturn=20241106182539
45.
Leverage GC. Obesity coverage nexus. (2024). Available at: https://leveragegc.com/rwjf/platform
46.
Hooper K. Diet drug boom weighs heavily on state budgets. Politico (2025). Available at: https://www.politico.com/news/2025/02/12/ozempic-state-budgets-00202932
47.
Lovelace B Jr, McLaughlin E, Kane J. How one state is trying to make weight loss drugs cheaper. NBC News (2024). Available at: https://www.nbcnews.com/health/health-news/one-state-trying-make-weight-loss-drugs-cheaper-rcna148997
48.
Prime Therapeutics. Prime Therapeutics GLP-1 research: year-2 cost of care is $4,200 higher for patients with obesity. (2024). Available at: https://www.primetherapeutics.com/w/prime-therapeutics-glp-1-research-year-2-cost-of-care-is-4-200-higher-for-patients-with-obesity#:∼:text=The%20findings%20indicate%20in%20the,in%207%20still%20taking%20a
49.
Sellers M. Blue Cross Blue Shield of Massachusetts faces record-breaking $400 million operating loss in 2024. Insurance Business Magazine (2025). Available at: https://www.insurancebusinessmag.com/us/news/life-insurance/blue-cross-blue-shield-of-massachusetts-faces-recordbreaking-400-million-operating-loss-in-2024-526958.aspx
50.
Logan J, Jarzombej R. Pharmacy benefits overview and Inflation Reduction Act (IRA) update. CalPERS (2024). Available at: https://www.calpers.ca.gov/documents/202409-pension-item-6b-attach-1-a/download
51.
Ippolito B, Levy JF. Expanding Medicare coverage of anti-obesity medicines could increase annual spending by $3.1 billion to $6.1 billion. Health Affairs 43(9), 1254–1262 (2024).
52.
Centers for Medicare & Medicaid Services, Department of Health and Human Services. Medicare and Medicaid programs; contract year 2026 policy and technical changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and programs of all-inclusive care for the elderly. (2024). Available at: https://public-inspection.federalregister.gov/2024-27939.pdf
53.
Congressional Budget Office. How would authorizing Medicare to cover anti-obesity medications affect the federal budget? (2024). Available at: https://www.cbo.gov/publication/60816#_idTextAnchor000
54.
RXSaveCard. Prescription costs are broken. We're fixing them. (2025). Available at: https://rxsavecard.com/?utm_source=costcurve.beehiiv.com&utm_medium=newsletter&utm_campaign=looking-at-the-pioneers-in-the-nacent-pharm-to-table-movement&_bhlid=5cbef8bcb1ba1a6bf0407e2aba9e12c547dfbdef
55.
56.
Eli Lilly. (2025). Available at: Reimagining healthcare. https://lillydirect.lilly.com/?utm_source=costcurve.beehiiv.com&utm_medium=newsletter&utm_campaign=looking-at-the-pioneers-in-the-nacent-pharm-to-table-movement&_bhlid=debc6ee051ebe74d5825673441d8f8859670cc2d
57.
Pearson SD, Towse A, Lowe M, Segel CS, Henshall C. Cornerstones of ‘fair’ drug coverage: appropriate cost sharing and utilization management policies for pharmaceuticals. J. Comp. Eff. Res. 10(7), 537–547 (2021).
58.
Food and Drug Administration. Highlights of prescribing information: wegovy (semaglutide). (2021). Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf
59.
Food and Drug Administration. Highlights of prescribing information: zepbound (tirzepatide). (2023). Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217806s005s006s011s015s019lbl.pdf
60.
Clark RL. GLP-1 drugs for weight loss: what employers need to know. Vita (2024). Available at: https://vitacompanies.com/blog/glp1-drugs-for-weight-loss-what-employers-need-to-know
61.
McGough M, Lo J, Tevis D, Rae M, Cox C. How many adults with private health insurance could use GLP-1 drugs. Peterson-KFF (2024). Available at: https://www.healthsystemtracker.org/brief/how-many-adults-with-private-health-insurance-could-use-glp-1-drugs/
62.
Blue Shield of California. Weight loss medication coverage change fact sheet. Blue Shield of California (2024). Available at: https://www.blueshieldca.com/content/dam/bsca/en/provider/docs/Weight-Loss-Drug-Exclusion-Fact-Sheet.pdf
63.
National Institute for Health and Care Excellence, National Health Service (NHS). Semaglutide for managing overweight and obesity. (2022). Available at: https://www.nice.org.uk/guidance/ta875/documents/final-appraisal-determination-document
64.
National Institute for Health and Care Excellence. Consultation on NHS England proposals for a phased launch of obesity injection. NICE, UK (2024). Available at: https://www.nice.org.uk/news/articles/consultation-on-nhs-england-proposals-for-a-phased-launch-of-obesity-injection
65.
Smith BM, Criminisi A, Sorek N et al. Modeling health risks using neural network ensembles. PLoS One 19(10), e0308922 (2024).
66.
FormHealth. Dedicated clinical care to make lasting change. FormHealth (2025). Available at: https://www.formhealth.co/how-it-works
67.
Phenomix Sciences. Phenomix Sciences and InformedDNA partner to advance genetics-driven obesity care. Phenomix Sciences (2024). Available at: https://www.phenomixsciences.com/about/press/phenomix-sciences-and-informeddna-partner-advance-genetics-driven-obesity-care#:∼:text=The%20MyPhenome%20test%20is%20a,treatments%2C%20including%20GLP%2D1s
68.
Prado CM, Phillips SM, Gonzalez MC, Heymsfield SB. Muscle matters: the effects of medically induced weight loss on skeletal muscle. Lancet 12(11), 785–787 (2024).
69.
Jensen SB, Sørensen V, Sandsdal RM et al. Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment: a secondary analysis of a randomized clinical trial. JAMA 7(6), e2416775 (2024).
70.
Palmer K. During JPM week, virtual care companies strut their plans to make GLP-1 drugs work harder, cost less. STAT (2025). Available at: https://www.statnews.com/2025/01/16/jp-morgan-conference-virtual-care-companies-glp-plans/
71.
Calibrate. Calibrate delivers longitudinal real-world outcomes with sustained weight loss and metabolic health improvements. Calibrate (2025). calibrate.cdn.priscmic.io. Available at: https://calibrate.cdn.prismic.io/calibrate/Z4VCK5bqstJ99ZFD_2025ResultsReportWhitePaper-1-.pdf
72.
Kim DD, Fendrick AM. An efficient approach to expand equitable access to antiobesity medications: deprescribing after weight loss plateau. Am. J. Manag. Care 30(8), 348–350 (2024).
73.
Office of the State Controller (OSC). Health care update. (2024). Available at: https://osc.ct.gov/empret/meetings/hcccc/pdfs/HC4_SlidesPublicMeeting3-2024.pdf
74.
Institute for Clinical and Economic Review. Cornerstones of ‘fair’ drug coverage. (2020). Available at: https://icer.org/assessment/cornerstones-of-fair-drug-coverage-2020/
75.
Liu HH, Mulcahy AW, Rose AJ. Subscription models for prescription drugs: the motivation, potential, and limitations of a new payment model. RAND Corporation (2020). Available at: https://www.rand.org/pubs/perspectives/PEA289-1.htmlhttps://www.rand.org/pubs/perspectives/PEA289-1.html
76.
Baghdadi R. Medicaid best price. HealthAffairs (2017). Available at: https://www.healthaffairs.org/content/briefs/medicaid-best-pricehttps://www.healthaffairs.org/content/briefs/medicaid-best-price
77.
Flyte Health. For employer-sponsored weight loss plans. (2025). Available at: https://www.joinflyte.com/
78.
Fitch ME. CT state employees losing weight on medication, but costs top $35 million. Inside Investigator (2024). Available at: https://insideinvestigator.org/ct-state-employees-losing-weight-on-medication-but-costs-top-35-million/
79.
Pifer R. Why Cigna is capping cost increases for pricey GLP-1 weight loss drugs. MedTechDive (2024). Available at: https://www.medtechdive.com/news/cigna-glp-1-cost-cap-employers-pbm/709770/
80.
118th Congress (2023–2024). (2023). H.R.4818 Treat and Reduce Obesity Act of 2023.
81.
Lovelace B Jr. House committee passes bill that would allow Medicare to cover weight loss drugs. NBC News (2024). Available at: https://www.nbcnews.com/health/health-news/house-committee-passes-bill-allow-medicare-cover-weight-loss-drugs-rcna159248
82.
Lovelace B Jr. ‘Novo Nordisk is ripping off the American people,’ Bernie Sanders says of Ozempic and Wegovy costs. NBC News (2024). Available at: https://www.nbcnews.com/health/health-news/bernie-sanders-ozempic-wegovy-drugmaker-ripping-us-weight-loss-drug-co-rcna157863
83.
U.S. Preventive Services Task Force. A & B recommendations. (2025). Available at: https://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics/uspstf-a-and-b-recommendations
84.
Centers for Medicare & Medicaid Services. Medicare drug price negotiation program: selected drugs for initial price applicability year 2027. (2025). http://www.cms.gov Available at: https://www.cms.gov/files/document/factsheet-medicare-negotiation-selected-drug-list-ipay-2027.pdf
85.
Centers for Medicare & Medicaid Services. Medicare drug price negotiation program. (2025). Available at: https://www.cms.gov/priorities/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program
86.
Nania R. Medicare unveils first negotiated prices for 10 of the costliest medications. AARP (2024). Available at: https://www.aarp.org/politics-society/advocacy/info-2024/medicare-drug-price-list.html
87.
Silverman E. North Carolina urges HHS to license Novo and Lilly obesity drugs as a way to lower costs. STAT (2024). Available at: https://www.statnews.com/pharmalot/2024/08/05/novo-lilly-carolina-hhs-becerra-obesity-weight-diabetes-sanders-biden-wegovy-ozempic-zepbound/
Information & Authors
Information
Published In
Copyright
© 2025 Institute for Clinical and Economic Review (ICER). This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License
History
Received: 23 May 2025
Accepted: 24 June 2025
Published online: 11 July 2025
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions in the US. (2025) Journal of Comparative Effectiveness Research. DOI: 10.57264/cer-2025-0083
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Usman Ali Akbar, Avilash Mondal, Mounica Vorla, Waleed Alruwaili, Jordan Lacoste, Harshith Thyagaturu, Nouman Shafique, Sana Shakeel, Amro Taha, Sudarshan Balla, Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Outcomes in Patients With Atherosclerotic Cardiovascular Disease and Obesity Without Diabetes, The American Journal of Cardiology, 10.1016/j.amjcard.2026.05.004, 272, (1-8), (2026).
- Luxcia Kugathasan, Alexandra Katz, Marcel H.A. Muskiet, Vikas S. Sridhar, Jennifer Scott, Tae Won Yi, David Z.I. Cherney, Novel Therapeutic Strategies for Patients With CKD and Diabetes Mellitus, Kidney International Reports, 10.1016/j.ekir.2026.106547, 11, 7, (106547), (2026).
- Isabella de Vere Hunt, Mariana Ramirez-Posada, Christopher Sam Babu, Cati Brown-Johnson, Eleni Linos, Fatima Rodriguez, Patient Experiences With GLP-1 Receptor Agonists, JAMA Network Open, 10.1001/jamanetworkopen.2026.16951, 9, 6, (e2616951), (2026).
- Sujith Ramachandran, Ben Urick, Tara Thomas, ICER report demonstrates both the value and challenges in financing of weight loss medications, Journal of Managed Care & Specialty Pharmacy, 10.18553/jmcp.2026.32.6.753, 32, 6, (753-757), (2026).
- Lydia Alexander, Jonathan Q. Purnell, Karlijn Burridge, Marc-André Cornier, Angela Golden, Deborah Bade Horn, Michelle Look, Joe Nadglowski, Camila Ávila-Oliver, Francisco Novillo, Ana María Rojas-Gómez, Brad Hussey, Ximena Ramos Salas, Joint TOS/OMA/OAC expert guidance statement on the pharmacological management of United States adults with overweight or obesity using the GRADE approach, Obesity Pillars, 10.1016/j.obpill.2026.100254, 18, (100254), (2026).
- Sean Kelleher, Samuel Ricci, Kyle Stump, Prasad Kanuparthi, Theodore C. Hannah, Neal Patel, Rohan Vij, Bong-Soo Kim, Glucagon-like peptide-1 receptor agonists and the risk of surgical intervention in idiopathic intracranial hypertension: A propensity-matched cohort study, Clinical Neurology and Neurosurgery, 10.1016/j.clineuro.2026.109372, 265, (109372), (2026).
- Nicole Trainer, The “microdosing” dilemma: Balancing patient anecdotes with clinical safety amid GLP-1 compounding restrictions, Journal of the American Association of Nurse Practitioners, 10.1097/JXX.0000000000001296, (2026).
- Molly Jacobs, Qianqian Fang, Charles Ellis, Trends in GLP-1 Receptor Agonist and SGLT2-Inhibitor Utilization and Expenditure Between 2017–2023: Demographic, Income, and Insurance Associations, Journal of General Internal Medicine, 10.1007/s11606-026-10408-4, (2026).
- Aya Bassatne, Ivania Rizo, Future Directions in the Medical Treatment of Obesity: A Narrative Review, Advances in Therapy, 10.1007/s12325-026-03576-6, 43, 6, (2387-2407), (2026).
- Ranganath Muniyappa, Tariq Chukir, Dimpi Desai, Michael A Weintraub, Maureen D Corrigan, Roma Gianchandani, Amy E Rothberg, Defining disease or delaying care? A conceptual and clinical appraisal of the Lancet obesity framework, The Journal of Clinical Endocrinology & Metabolism, 10.1210/clinem/dgag097, 111, 6, (1503-1512), (2026).
- See more